e.l.f. Beauty (ELF) Q4 2026 Earnings Transcript

e.l.f. Beauty reported Q4 net sales growth of 35% and full-year growth of 25%, but profitability weakened as Q4 adjusted EBITDA fell to $59 million from $81 million and adjusted EPS dropped to $0.32 from $0.78. Management guided fiscal 2027 net sales growth of 12%-14% and adjusted EBITDA of $379 million-$385 million, while flagging slower e.l.f. brand consumption, higher investment, and ongoing tariff exposure despite a lower assumed 35% tariff rate. Rhode remained a major growth driver, contributing $113 million in Q4 sales and roughly 9 points to FY27 growth, while cash rose to $290 million and $400 million remained available under buybacks.

Analysis

The setup is better understood as a portfolio transition rather than a clean growth inflection. The core brand is now behaving like a mature, highly competitive value franchise: pricing can protect revenue, but unit elasticity is telling us the easy share gains are behind them for now. That matters because the next leg of upside has to come from either a faster innovation cadence or a more aggressive price/value reset; both are execution-dependent and will likely show up first in unit velocity before they show up in reported sales.

The biggest second-order positive is that Rhode is de-risking the earnings bridge, but it is also quietly changing the mix quality of the business. As Rhode scales into retail, the company trades higher-margin DTC scarcity economics for broader distribution, which should support topline but cap operating leverage in the near term. That mix shift is why margins can look mechanically flat even if the brand comp is strong: growth is increasingly coming from a brand portfolio that needs more inventory, more retail support, and more marketing to keep demand ahead of supply.

The market may be underappreciating how much tariff normalization and supply-chain diversification improve optionality into the back half of the year. If rates stay near current levels and the refund is realized, the company gets a non-recurring funding source to subsidize value actions without blowing up EBITDA. That creates a path to defend the core brand while preserving the longer-duration thesis on international and skincare expansion; the main risk is that the consumer response to pricing is structural, not temporary, which would force a deeper reset in average selling price and retailer economics over the next 2-3 quarters.

Key Decisions for Investors

• Long ELF on a 3-6 month horizon, but size it as a catalyst-driven trade rather than a secular compounder until unit trends stabilize; upside comes from tariff refund realization plus a cleaner second-half organic reacceleration, while downside is a second pricing misstep that compresses units further.
• Pair trade: long ELF / short a basket of premium beauty beneficiaries with rich multiples and slower growth, on the view that value-led share gains and Rhode expansion are more defensible than prestige sell-through assumptions over the next 2 quarters.
• Buy ELF Jan-2027 call spreads after the first evidence of unit recovery from the value tests; the convexity is attractive because successful price optimization can lift units without requiring a full re-rating of the core business.
• For tactically bearish exposure, short-dated ELF puts into any pre-holiday innovation disappointment would express the risk that the core brand remains structurally weaker than management’s base case; the window is the next 6-10 weeks when intervention results should become visible.
• Watch AMZN and ULTA as indirect beneficiaries of any successful price-reset cycle: if ELF drives more traffic and conversion through lower-ticket items, those channels should gain share in beauty discovery and replenishment, supporting a modest long bias in the retail platforms on dips.